Embedded Files
Join us in transforming how the world fights cancer. SUMOdulon, Inc. is seeking strategic investors who share our vision of making chemotherapy resistance a problem of the past.
The Opportunity
The Opportunity
Chemotherapy resistance affects millions of cancer patients worldwide. Despite decades of advances in oncology, there is still no approved therapy specifically designed to prevent or reverse this resistance. The global market for chemotherapy sensitizers and resistance modulators represents a $2.5 billion opportunity across three priority cancer types alone.
SUMOdulon, Inc. is uniquely positioned to capture this market with a first-in-class pipeline, university-backed research, and a lead compound already validated in preclinical laboratory studies.
Where We Are Today
Where We Are Today
2023
2023
Year SUMOdulon, Inc. was incorporated in El Paso, Texas
$20K
$20K
Seed funding secured through the 2024 Elevate Health Tech Challenge
TRL 4
TRL 4
Technology Readiness Level achieved through rigorous preclinical laboratory validation
How Your Investment Will Be Used
How Your Investment Will Be Used
SUMOdulon, Inc. is seeking investment to advance our pipeline from preclinical validation toward clinical development. Funds will be deployed strategically across three key areas:
Research & Development
Research & Development
Advancing SUM2IN and our broader pipeline through Phase 2 preclinical studies and preparing for Investigational New Drug (IND) application filing.
Intellectual Property
Intellectual Property
Securing and expanding patent protection for our pipeline compounds to establish a strong competitive moat in the SUMOylation inhibitor space.
Team & Operations
Team & Operations
Building out the core team, establishing operational infrastructure, and advancing business development and commercialization activities.
Our Exit Strategy
Our Exit Strategy
SUMOdulon, Inc. is building long-term value with a clear path to investor returns. Our strategy follows a proven biotech commercialization model with two primary exit pathways.
Strategic Acquisition
Strategic Acquisition
As our pipeline advances toward clinical trials, SUMOdulon becomes an attractive acquisition target for major pharmaceutical companies seeking first-in-class oncology assets.
Initial Public Offering (IPO)
Initial Public Offering (IPO)
Upon successful clinical validation, SUMOdulon may pursue an IPO, providing investors with liquidity and long-term growth potential in the oncology market.
We welcome conversations with investors, strategic partners, and grant-providing organizations who share our mission. Reach out to us directly and let's explore what we can build together.
Page updated
Google Sites
Report abuse